PortfoliosLab logoPortfoliosLab logo
Gilead Sciences, Inc. (GILD)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US3755581036
CUSIP
375558103
IPO Date
Jan 22, 1992

Highlights

Market Cap
$174.63B
Enterprise Value
$164.03B
EPS (TTM)
$6.79
PE Ratio
20.54
PEG Ratio
0.05
Total Revenue (TTM)
$29.44B
Gross Profit (TTM)
$23.79B
EBITDA (TTM)
$12.90B
Year Range
$93.37 - $157.29
Target Price
$154.20
ROA (TTM)
14.42%
ROE (TTM)
37.62%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Gilead Sciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Gilead Sciences, Inc. (GILD) has returned 14.19% so far this year and 27.69% over the past 12 months. Over the last ten years, GILD has returned 7.74% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.


Gilead Sciences, Inc.

1D
2.22%
1M
-5.90%
YTD
14.19%
6M
27.11%
1Y
27.69%
3Y*
22.97%
5Y*
20.37%
10Y*
7.74%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Jan 22, 1992, GILD's average daily return is +0.11%, while the average monthly return is +2.05%. At this rate, your investment would double in approximately 2.8 years.

Historically, 55% of months were positive and 45% were negative. The best month was Feb 2000 with a return of +63.4%, while the worst month was Jun 1996 at -31.4%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 7 months.

On a daily basis, GILD closed higher 50% of trading days. The best single day was Apr 28, 2000 with a return of +24.8%, while the worst single day was Jul 15, 1996 at -26.6%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202615.65%4.93%-5.90%14.19%
20255.23%17.60%-1.29%-4.92%3.32%1.43%1.28%0.61%-1.06%7.92%5.05%-1.82%36.59%
2024-3.39%-7.87%2.64%-10.99%-1.43%8.06%10.86%3.87%7.12%5.94%4.23%0.61%18.68%
2023-2.22%-4.06%4.01%-0.92%-6.41%1.14%-1.21%0.45%-1.05%4.80%-2.47%6.72%-1.99%
2022-5.41%-12.06%-0.32%-0.19%9.29%-3.50%-3.33%6.23%-1.70%27.18%11.94%-1.44%23.63%
202112.60%-6.40%6.46%-1.79%4.16%5.25%-0.83%6.57%-3.06%-7.12%6.24%6.41%29.95%

Benchmark Metrics

Gilead Sciences, Inc. has an annualized alpha of 21.35%, beta of 0.87, and R² of 0.11 versus S&P 500 Index. Calculated based on daily prices since January 23, 1992.

  • This stock captured 104.11% of S&P 500 Index gains but only 55.47% of its losses — a favorable profile for investors.
  • R² of 0.11 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
21.35%
Beta
0.87
0.11
Upside Capture
104.11%
Downside Capture
55.47%

Return for Risk

Risk / Return Rank

GILD ranks 72 for risk / return — better than 72% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


GILD Risk / Return Rank: 7272
Overall Rank
GILD Sharpe Ratio Rank: 7373
Sharpe Ratio Rank
GILD Sortino Ratio Rank: 6868
Sortino Ratio Rank
GILD Omega Ratio Rank: 6363
Omega Ratio Rank
GILD Calmar Ratio Rank: 7777
Calmar Ratio Rank
GILD Martin Ratio Rank: 7878
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Gilead Sciences, Inc. (GILD) and compare them to a chosen benchmark (S&P 500 Index).


GILDBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.96

0.90

+0.06

Sortino ratio

Return per unit of downside risk

1.55

1.39

+0.17

Omega ratio

Gain probability vs. loss probability

1.18

1.21

-0.03

Calmar ratio

Return relative to maximum drawdown

2.03

1.40

+0.63

Martin ratio

Return relative to average drawdown

5.55

6.61

-1.06

Explore GILD risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History

Gilead Sciences, Inc. provided a 2.29% dividend yield over the last twelve months, with an annual payout of $3.19 per share. The company has been increasing its dividends for 10 consecutive years.


1.00%2.00%3.00%4.00%5.00%$0.00$0.50$1.00$1.50$2.00$2.50$3.00$3.5020152016201720182019202020212022202320242025
Dividends
Dividend Yield
PeriodTTM20252024202320222021202020192018201720162015
Dividend$3.19$3.16$3.08$3.00$2.92$2.84$2.72$2.52$2.28$2.08$1.84$1.29

Dividend yield

2.29%2.57%3.33%3.70%3.40%3.91%4.67%3.88%3.65%2.90%2.57%1.27%

Monthly Dividends

The table displays the monthly dividend distributions for Gilead Sciences, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026$0.00$0.00$0.82$0.82
2025$0.00$0.00$0.79$0.00$0.00$0.79$0.00$0.00$0.79$0.00$0.00$0.79$3.16
2024$0.00$0.00$0.77$0.00$0.00$0.77$0.00$0.00$0.77$0.00$0.00$0.77$3.08
2023$0.00$0.00$0.75$0.00$0.00$0.75$0.00$0.00$0.75$0.00$0.00$0.75$3.00
2022$0.00$0.00$0.73$0.00$0.00$0.73$0.00$0.00$0.73$0.00$0.00$0.73$2.92
2021$0.00$0.00$0.71$0.00$0.00$0.71$0.00$0.00$0.71$0.00$0.00$0.71$2.84

Dividend Yield & Payout


Dividend Yield

Gilead Sciences, Inc. has a dividend yield of 2.29%, which is quite average when compared to the overall market.

Payout Ratio

Gilead Sciences, Inc. has a payout ratio of 35.36%, which is quite average when compared to the overall market. This suggests that Gilead Sciences, Inc. strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Gilead Sciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Gilead Sciences, Inc. was 70.83%, occurring on Jun 6, 1994. Recovery took 300 trading sessions.

The current Gilead Sciences, Inc. drawdown is 10.04%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-70.83%Jan 28, 1992596Jun 6, 1994300Aug 11, 1995896
-60.44%Sep 26, 1997234Aug 31, 1998127Mar 4, 1999361
-59.68%Sep 8, 199973Dec 20, 1999169Aug 21, 2000242
-57.67%Feb 1, 1996114Jul 15, 1996298Sep 17, 1997412
-53.48%Sep 26, 200073Jan 9, 200191May 21, 2001164

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Gilead Sciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Gilead Sciences, Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for GILD, comparing it with other companies in the Drug Manufacturers - General industry. Currently, GILD has a P/E ratio of 20.5. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for GILD compared to other companies in the Drug Manufacturers - General industry. GILD currently has a PEG ratio of 0.1. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for GILD relative to other companies in the Drug Manufacturers - General industry. Currently, GILD has a P/S ratio of 5.9. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for GILD in comparison with other companies in the Drug Manufacturers - General industry. Currently, GILD has a P/B value of 7.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items